Galenica sets stage for split; Vifor exposed
This article was originally published in Scrip
Swiss firm Galenica has laid the foundation for splitting itself into two independently listed companies. Analysts believe the new structure exposes its pharmaceutical division Vifor Pharma as a prime acquisition target. "In our opinion, even though a separate listing of its businesses is not being envisaged shortly, Galenica's new structure exposes its pharmaceutical unit as a takeout target," said Helvea analysts.